Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy (original) (raw)
References
Katz MF, Farber HW, Dodds-Stitt Z, Cruikshank WW, Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic, growth factor. J Leukoc Biol 1994;55:567–73. ArticleCASPubMed Google Scholar
Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor, its antagonists in the cardiovascular system. Pharmacol Ther 2004;104:59–81. ArticleCASPubMed Google Scholar
Saxena PR, Villalon CM. Cardiovascular effects of serotonin agonists, antagonists. J Cardiovasc Pharmacol 1990;15(Suppl 7):S17–34. ArticleCASPubMed Google Scholar
Eto Y, Nitta K, Uchida K, Tsutsui T, Natori K, Kawashima A, et al. Anti-mitogenic effects of sarpogrelate in cultured rat mesangial cells. Life Sci 1997;60:PL193–9. ArticleCASPubMed Google Scholar
Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus, peripheral vascular disease. Eur J Clin Invest 1988;18:399–404. ArticleCASPubMed Google Scholar
Kasho M, Sakai M, Sasahara T, Anami Y, Matsumura T, Takemura T, et al. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int 1998;54:1083–92. ArticleCASPubMed Google Scholar
Ogawa S, Takeuchi K, Sugimura K, Sato C, Fukuda M, Lee R, et al. The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin Exp Pharmacol Physiol 1999;26:461–4. ArticleCASPubMed Google Scholar
Takahashi T, Yano M, Minami J, Haraguchi T, Koga N, Higashi K, et al. Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res Clin Pract 2002;58:123–9. ArticleCASPubMed Google Scholar
Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988;296:156–60. ArticleCAS Google Scholar
Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005;288:F1144–52. ArticleCASPubMed Google Scholar
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27–36. ArticleCASPubMed Google Scholar
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540–6. ArticleCASPubMed Google Scholar
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, treatment. Diabetes Care 2005;28:164–76. ArticlePubMed Google Scholar
VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277–87. ArticleCASPubMed Google Scholar
Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995;116:235–40. ArticleCASPubMed Google Scholar
Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y, et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 1999;81:271–7. ArticleCASPubMed Google Scholar
Yamashita T, Kitamori K, Hashimoto M, Watanabe S, Giddings JC, Yamamoto J. Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. Haemostasis 2000;30:321–32. CASPubMed Google Scholar
Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991;65:415–20. CASPubMed Google Scholar
Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets, microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001;158:277–87. ArticleCASPubMed Google Scholar
Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003;26:285–9. ArticleCASPubMed Google Scholar
Lin J, Hu FB, Curhan G. Serum adiponectin, renal dysfunction in men with type 2 diabetes. Diabetes Care 2007;30:239–44. ArticleCASPubMed Google Scholar
Yamakawa J, Takahashi T, Itoh T, Kusaka K, Kawaura K, Wang XQ, et al. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care 2003;26:2477–8. ArticlePubMed Google Scholar
Kokubu N, Tsuchihashi K, Yuda S, Hase M, Eguchi M, Wakabayashi T, et al. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J 2006;70:1451–6. ArticleCASPubMed Google Scholar
Guo Z, Xia Z, Yuen VG, McNeill JH. Cardiac expression of adiponectin, its receptors in streptozotocin-induced diabetic rats. Metabolism 2007;56:1363–71. ArticleCASPubMed Google Scholar
Ito T, Ikeda U, Shimpo M, Yamamoto K, Shimada K. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 2000;102:2522–7. ArticleCASPubMed Google Scholar